1
|
Bourrion B, Panjo H, François M, Pelletier-Fleury N. Trends in clomiphene citrate and gonadotropins use in women with infertility between 2010 and 2017: A population-based study in France. Pharmacoepidemiol Drug Saf 2023; 32:845-854. [PMID: 36935527 DOI: 10.1002/pds.5616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 01/31/2023] [Accepted: 03/16/2023] [Indexed: 03/21/2023]
Abstract
PURPOSE To describe temporal trends and assess factors associated with changes in the prescription of clomiphene citrate and gonadotropins between 2010 and 2017 in women with infertility aged 18-50 from metropolitan France. METHODS 6321 prevalent women from a representative sample of the national medico-administrative database were identified. We performed a Cochran-Armitage trend test and calculated the rate ratios. A Poisson regression was used to derive the incidence rate ratios, for each treatment class. RESULTS The prevalence rate and incidence rate of clomiphene citrate use significantly decreased by 20% (RR 0.80: 95% CI 0.71-0.90) and 23% (RR 0.77: 95% CI 0.66-0.89), respectively. Its initiation was higher in all age groups compared to the reference (18-24 years), with a downward gradient. It was also higher when the density of gynaecologists was higher and in disadvantaged areas. The prevalence rate and incidence rate of gonadotropin use increased by 11% (RR 1.11: 95% CI 1.01-1.22) and 33% (RR 1.33: 95% CI 1.14-1.55) respectively. Gonadotropin initiation was highest in the 31-35 age group, but it was also higher in the 25-30 and 36-40 age groups at a similar level (reference 18-24 years). Its initiation was higher when the density of gynaecologists was higher, but not associated with social deprivation. CONCLUSION Our results showed an increase in gonadotropin use for infertility treatment in France during the 2010-2017 period and a decrease in clomiphene citrate use. Further work should be undertaken to analyse the use of these drugs in relation to women's care pathways.
Collapse
Affiliation(s)
- Bastien Bourrion
- INSERM, Université Paris-Saclay, UVSQ, CESP, bâtiment 15/16 Inserm, Hôpital Paul Brousse, 16 Avenue Paul Vaillant Couturier, 94807, Villejuif Cedex, France
- Département de Médecine Générale, UVSQ, Faculté des Sciences de la Santé Simone Veil, Montigny le Bretonneux, France
| | - Henri Panjo
- INSERM, Université Paris-Saclay, UVSQ, CESP, bâtiment 15/16 Inserm, Hôpital Paul Brousse, 16 Avenue Paul Vaillant Couturier, 94807, Villejuif Cedex, France
| | - Mathilde François
- INSERM, Université Paris-Saclay, UVSQ, CESP, bâtiment 15/16 Inserm, Hôpital Paul Brousse, 16 Avenue Paul Vaillant Couturier, 94807, Villejuif Cedex, France
- Département de Médecine Générale, UVSQ, Faculté des Sciences de la Santé Simone Veil, Montigny le Bretonneux, France
| | - Nathalie Pelletier-Fleury
- INSERM, Université Paris-Saclay, UVSQ, CESP, bâtiment 15/16 Inserm, Hôpital Paul Brousse, 16 Avenue Paul Vaillant Couturier, 94807, Villejuif Cedex, France
| |
Collapse
|
2
|
Choi SKY, Venetis C, Ledger W, Havard A, Harris K, Norman RJ, Jorm LR, Chambers GM. Population-wide contribution of medically assisted reproductive technologies to overall births in Australia: temporal trends and parental characteristics. Hum Reprod 2022; 37:1047-1058. [DOI: 10.1093/humrep/deac032] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 01/27/2022] [Indexed: 11/14/2022] Open
Abstract
Abstract
STUDY QUESTION
In a country with supportive funding for medically assisted reproduction (MAR) technologies, what is the proportion of MAR births over-time?
SUMMARY ANSWER
In 2017, 6.7% of births were conceived by MAR (4.8% ART and 1.9% ovulation induction (OI)/IUI) with a 55% increase in ART births and a stable contribution from OI/IUI births over the past decade.
WHAT IS KNOWN ALREADY
There is considerable global variation in utilization rates of ART despite a similar infertility prevalence worldwide. While the overall contribution of ART to national births is known in many countries because of ART registries, very little is known about the contribution of OI/IUI treatment or the socio-demographic characteristics of the parents. Australia provides supportive public funding for all forms of MAR with no restrictions based on male or female age, and thus provides a unique setting to investigate the contribution of MAR to national births as well as the socio-demographic characteristics of parents across the different types of MAR births.
STUDY DESIGN, SIZE, DURATION
This is a novel population-based birth cohort study of 898 084 births using linked ART registry data and administrative data including birth registrations, medical services, pharmaceuticals, hospital admissions and deaths. Birth (a live or still birth of at least one baby of ≥400 g birthweight or ≥20 weeks’ gestation) was the unit of analysis in this study. Multiple births were considered as one birth in our analysis.
PARTICIPANTS/MATERIALS, SETTING, METHODS
This study included a total of 898 084 births (606 488 mothers) in New South Wales and the Australian Capital Territory, Australia 2009–2017. We calculated the prevalence of all categories of MAR-conceived births over the study period. Generalized estimating equations were used to examine the association between parental characteristics (parent’s age, parity, socio-economic status, maternal country of birth, remoteness of mother’s dwelling, pre-existing medical conditions, smoking, etc.) and ART and OI/IUI births relative to naturally conceived births.
MAIN RESULTS AND THE ROLE OF CHANCE
The proportion of MAR births increased from 5.1% of all births in 2009 to 6.7% in 2017, representing a 30% increase over the decade. The proportion of OI/IUI births remained stable at around 2% of all births, representing 32% of all MAR births. Over the study period, ART births conceived by frozen embryo-transfer increased nearly 3-fold. OI/IUI births conceived using clomiphene citrate decreased by 39%, while OI/IUI births conceived using letrozole increased 56-fold. Overall, there was a 55% increase over the study period in the number of ART-conceived births, rising to 56% of births to mothers aged 40 years and older. In 2017, almost one in six births (17.6%) to mothers aged 40 years and over were conceived using ART treatment. Conversely, the proportion of OI/IUI births was similar across different mother’s age groups and remained stable over the study period. ART children, but not OI/IUI children, were more likely to have parents who were socio-economically advantaged compared to naturally conceived children. For example, compared to naturally conceived births, ART births were 16% less likely to be born to mothers who live in the disadvantaged neighbourhoods after accounting for other covariates (adjusted relative risk (aRR): 0.84 [95% CI: 0.81–0.88]). ART- or OI/IUI-conceived children were 25% less likely to be born to immigrant mothers than births after natural conception (aRR: 0.75 [0.74–0.77]).
LIMITATIONS, REASONS FOR CAUTION
The social inequalities that we observed between the parents of children born using ART and naturally conceived children may not directly reflect disparities in accessing fertility care for individuals seeking treatment.
WIDER IMPLICATIONS OF THE FINDINGS
With the ubiquitous decline in fertility rates around the world and the increasing trend to delay childbearing, this population-based study enhances our understanding of the contribution of different types of MARs to population profiles among births in high-income countries. The parental socio-demographic characteristics of MAR-conceived children differ significantly from naturally conceived children and this highlights the importance of accounting for such differences in studies investigating the health and development of MAR-conceived children.
STUDY FUNDING/COMPETING INTEREST(S)
This study was funded through Australian National Health and Medical Research Council (NHMRC) grant: APP1127437. G.M.C. is an employee of The University of New South Wales (UNSW) and Director of the National Perinatal Epidemiology and Statistics Unit (NPESU), UNSW. The NPESU manages the Australian and New Zealand Assisted Reproduction Database with funding support from the Fertility Society of Australia and New Zealand. C.V. is an employee of The University of New South Wales (UNSW), Director of Clinical Research of IVFAustralia, Member of the Board of the Fertility Society of Australia and New Zealand, and Member of Research Committee of School of Women’s and Children’s Health, UNSW. C.V. reports grants from Australian National Health and Medical Research Council (NHMRC), and Merck KGaA. C.V. reports consulting fees, and payment or honoraria for lectures, presentations, speakers, bureaus, manuscript, writing or educational events or attending meeting or travel from Merck, Merck Sparpe & Dohme, Ferring, Gedon-Richter and Besins outside this submitted work. C.V. reported stock or stock options from Virtus Health Limited outside this submitted work. R.J.N. is an employee of The University of Adelaide, and Chair DSMC for natural therapies trial of The University of Hong Kong. R.J.N. reports grants from NHMRC. R.J.N. reports lecture fees and support for attending or travelling for lecture from Merck Serono which is outside this submitted work. L.R.J. is an employee of The UNSW and Foundation Director of the Centre for Big Data Research in Health at UNSW Sydney. L.R.J. reports grants from NHMRC. The other co-authors have no conflict of interest.
TRIAL REGISTRATION NUMBER
N/A.
Collapse
Affiliation(s)
- Stephanie K Y Choi
- National Perinatal Epidemiology and Statistics Unit (NPESU), Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
- School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Christos Venetis
- National Perinatal Epidemiology and Statistics Unit (NPESU), Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
- School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - William Ledger
- School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Alys Havard
- National Perinatal Epidemiology and Statistics Unit (NPESU), Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
- National Drug and Alcohol Research Centre, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Katie Harris
- The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Robert J Norman
- The Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia
| | - Louisa R Jorm
- National Perinatal Epidemiology and Statistics Unit (NPESU), Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Georgina M Chambers
- National Perinatal Epidemiology and Statistics Unit (NPESU), Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
- School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| |
Collapse
|
3
|
Ben Messaoud K, Bouyer J, de La Rochebrochard E. Infertility Treatment in France, 2008-2017: A Challenge of Growing Treatment Needs at Older Ages. Am J Public Health 2020; 110:1418-1420. [PMID: 32673116 DOI: 10.2105/ajph.2020.305781] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Objectives. To measure trends in infertility treatment use between 2008 and 2017 in France using data from the national health insurance system.Methods. Between 2008 and 2017, we observed a representative national sample of nearly 1% of all women aged 20 to 49 years who were affiliated with the main health insurance scheme in France (more than 100 000 women observed each year). We exhaustively recorded all health care reimbursed to these women.Results. Among women aged 20 to 49 years, 1.25% were treated for infertility each year. Logistic regression analysis showed a significant interaction between age and year of treatment use (P < .001). Over the decade, infertility treatment use increased by 23.9% among women aged 34 years or older, whereas among women younger than 34 years there was a nonsignificant variation.Conclusions. Women aged 34 years or older were increasingly treated for infertility between 2008 and 2017.Public Health Implications. Treatment efficiency decreases strongly with a woman's age, presenting a challenge for medical infertility care.
Collapse
Affiliation(s)
- Khaoula Ben Messaoud
- Khaoula Ben Messaoud is a PhD candidate with and Jean Bouyer and Elise de La Rochebrochard are with the Sexual and Reproductive Health and Rights Unit, Institut national d'etudes démographiques, Aubervilliers, France, and Institut national de la santé et de la recherche médicale, Université Paris-Saclay, Kremlin-Bicêtre, France
| | - Jean Bouyer
- Khaoula Ben Messaoud is a PhD candidate with and Jean Bouyer and Elise de La Rochebrochard are with the Sexual and Reproductive Health and Rights Unit, Institut national d'etudes démographiques, Aubervilliers, France, and Institut national de la santé et de la recherche médicale, Université Paris-Saclay, Kremlin-Bicêtre, France
| | - Elise de La Rochebrochard
- Khaoula Ben Messaoud is a PhD candidate with and Jean Bouyer and Elise de La Rochebrochard are with the Sexual and Reproductive Health and Rights Unit, Institut national d'etudes démographiques, Aubervilliers, France, and Institut national de la santé et de la recherche médicale, Université Paris-Saclay, Kremlin-Bicêtre, France
| |
Collapse
|
4
|
Helmy MEE, Maher MA, Elkhouly NI, Ramzy M. A randomized trial of local endometrial injury during ovulation induction cycles. Int J Gynaecol Obstet 2017; 138:47-52. [PMID: 28397981 DOI: 10.1002/ijgo.12178] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Revised: 02/08/2017] [Accepted: 04/07/2017] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To investigate the effect of endometrial injury on pregnancy outcomes among infertile women taking clomifene citrate. METHODS A prospective randomized trial was undertaken at an Egyptian hospital between January 26, 2015, and July 17, 2016. Eligible women (≥1 year primary/secondary/unexplained infertility, aged 20-35 years, day-2 follicle-stimulating hormone <12 IU/L, normal prolactin/thyroid function/uterine cavity, ≥1 patent tube, male partner with normal semen count and motility, 3 cycles of clomifene citrate without success) were randomly allocated (1:1) using computer-generated numbers into intervention (received endometrial injury on cycle day 15-24) or control groups (sham procedure). Women began ovulation induction on days 3-5 of the following cycle. Participants and investigators were not masked to group assignment. The primary outcomes were clinical pregnancy, spontaneous abortion, and multiple pregnancy rates. Women who completed follow-up were included in analyses. RESULTS The intervention group included 52 women and the control group 53 women. The clinical pregnancy rate was significantly higher in the intervention group (37% [n=19]) than in the control group (13% [n=7]; P=0.006). No differences between the intervention and control groups were noted for spontaneous abortion rate (11% [2/19] vs 29% [2/7]; P=0.287) or multiple pregnancy rate (11% [2/19] vs 14% [1/7]; P=0.790). No adverse effects were reported. CONCLUSION Endometrial injury before ovulation induction could improve chances of pregnancy and its outcomes. CLINICALTRIALS.GOV: NCT02345837.
Collapse
Affiliation(s)
- Medhat E E Helmy
- Obstetrics and Gynecology Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt
| | - Mohammad A Maher
- Obstetrics and Gynecology Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt
| | - Nabih I Elkhouly
- Obstetrics and Gynecology Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt
| | - Mahmoud Ramzy
- Obstetrics and Gynecology Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt
| |
Collapse
|
5
|
Effect of advanced maternal age on perinatal outcomes in twins: the impact of chorionicity. Ann Epidemiol 2013; 23:428-34. [PMID: 23790347 DOI: 10.1016/j.annepidem.2013.05.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2013] [Revised: 05/01/2013] [Accepted: 05/19/2013] [Indexed: 11/22/2022]
Abstract
PURPOSE In contrast to singletons, twins born to older mothers have lower rates of perinatal mortality than twins born to younger mothers. We examined whether differences in chorionicity could explain this unexpected maternal age effect. METHODS We used population-based data on twins born to mothers aged 20-29 (n = 3702) and ≥35 years (n = 1880) in the North of England, UK, 1998-2007. We calculated rate ratios (RR) and 95% confidence intervals (CIs) to estimate the effect of maternal age; adjusted RRs (ARRs) were estimated by the use of generalized estimating equations for Poisson regression controlling for chorionicity and other confounders. RESULTS Older mothers had a lower proportion of monochorionic twins (17.6% vs. 24.3%, P < .01); lower neonatal (RR, 0.57; 95% CI, 0.34-0.95) and perinatal mortality (RR, 0.74; 95% CI, 0.53-1.04). Adjustment for chorionicity attenuated these associations (ARR, 0.59; 95% CI, 0.35-0.98 and ARR, 0.80; 95% CI, 0.57-1.12, respectively) and after further adjustment for additional factors, both associations became nonsignificant. Older mothers had greater rates of small-for-gestational-age infants (ARR, 1.59; 95% CI, 1.24-2.05), and cesarean delivery (ARR, 1.31; 95% CI, 1.16-1.48). CONCLUSIONS Perinatal death rates were lower but not statistically different for twins born to older versus younger mothers. This association was attenuated by adjustment for chorionicity.
Collapse
|
6
|
Dijkstra A, Hak E, Janssen F. A systematic review of the application of spatial analysis in pharmacoepidemiologic research. Ann Epidemiol 2013; 23:504-14. [PMID: 23830932 DOI: 10.1016/j.annepidem.2013.05.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Revised: 05/23/2013] [Accepted: 05/23/2013] [Indexed: 11/18/2022]
Abstract
PURPOSE Although current reviews of the use of spatial analysis in general epidemiologic research illustrate an important and well-established role in exploring and predicting health, its application has not been reviewed in the subspecialty field of pharmacoepidemiology. METHODS We systematically reviewed the scientific literature to assess to what extent spatial analysis has been applied in pharmacoepidemiologic research and explored its potential added value. RESULTS A systematic search in PubMed and Embase/MEDLINE yielded 823 potentially relevant articles; 45 articles met our criteria for review. The studies were reviewed on study objective, applied spatial methods and units of analysis, and author-reported added value of the geographic approach used. Of the 45 included studies, 34 (76%) reported a geographic research objective. Comparative spatial methods were most often used (n = 25; 56%). Eleven studies used spatial statistics (32%); cluster analysis (n = 5) and aggregate data analysis (n = 4) being most common. Mapping was done in 15 studies (33%). The most common added value reported was to aid the planning of health policies and interventions (n = 24; 53%). A minority of pharmacoepidemiologic studies used a geographic approach and the applied methods were less advanced compared with the broader field of epidemiology. CONCLUSIONS Further advancements are needed to incorporate currently available spatial techniques to impact health care planning.
Collapse
Affiliation(s)
- Aletta Dijkstra
- Unit of PharmacoEpidemiology & PharmacoEconomics (PE(2)), Department of Pharmacy, University of Groningen, The Netherlands.
| | | | | |
Collapse
|